Key Takeaways The Street bailed on HALO in the spring, right before a summer rally on big growth2026 profit projections, among five analysts, jumped 17.7% from $6.43 to$7.57HALO shares still trade under 11 times next year's EPS consensusHalozyme Therapeutics ((HALO) is a $9 billion biotech focused on oncology and boasting sales and profit growth of 29% and 46%, respectively, while trading a sub-11x forward P/E.HALO is focused on the development and commercialization of novel treatments for oncology indicat ...